Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

September

28

Neurolens Introduces N3

An immersive, virtual-reality-based measurement and education experience DALLAS, September 28, 2023 –Powered by over ten billion data...

27

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)

Two prospective, peer-reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD...

26

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

6

TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics

Devlin Brings Significant Expertise in Commercialization, Sales and Marketing DENVER–(BUSINESS WIRE)–Sep. 6, 2023– TriSalus...

10

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

DENVER & FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Aug. 10, 2023– TriSalus Life Sciences® Inc., (TriSalus or the Company), an...

9

electroCore Announces Second Quarter 2023 Financial Results

Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter...

7

Exagen Inc. Reports Strong Second Quarter 2023 Results

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

3

ATEC Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance

CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to...

31

electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules

ROCKAWAY, N.J., July 31, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”),...

25

gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

ROCKAWAY, N.J., July 25, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and...

24

Exagen Inc. Appoints Paul Kim to Board of Directors

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

18

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

Recent developments

News

September

28

Neurolens Introduces N3

September

27

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)

September

26

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

September

6

TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics

August

10

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

August

9

electroCore Announces Second Quarter 2023 Financial Results

August

7

Exagen Inc. Reports Strong Second Quarter 2023 Results

August

3

ATEC Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance

July

31

electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules

July

25

gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

July

24

Exagen Inc. Appoints Paul Kim to Board of Directors

July

18

electroCore Expands Intellectual Patent Portfolio for nVNS Technology